Cell Medica Opens a Central European Manufacturing Facility in Berlin–Buch (Germany)  
9/26/2013 10:04:58 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

LONDON--(BUSINESS WIRE)--Cell Medica, a leading T cell therapeutics company, today announced the opening of its European commercial manufacturing facility at the Max-Delbrück-Center of Molecular Medicine within the biotechnology park of Campus Berlin-Buch (Germany). This state-of-the-art facility for the GMP production of cell and gene therapies includes approximately 350 m2 clean room space. Initial manufacturing will focus on Cytovir™ CMV – an innovative treatment which uses the immune cells of a healthy donor to restore viral immunity against Cytomegalovirus infections in patients who are immunocompromized following allogeneic hematopoietic stem cell (bone marrow) transplant. The commercial launch of this product is planned in early 2014 and will confirm Cell Medica’s position as one of the leaders in the development and market delivery of T cell therapeutics – a new paradigm for the treatment of cancer and infections.

Help employers find you! Check out all the jobs and post your resume.